Valproate-associated coagulopathies in children during short-term treatment

Area of Science:

• Neurology
• Hematology
• Pharmacology

Background:

• Valproic acid is a common antiepileptic drug for various epilepsies.
• Valproate is known to cause hemostatic disorders, including thrombocytopenia and altered platelet function.
• Potential links to atherosclerosis and thrombosis exist, but data on incidence and occurrence are limited.

Purpose of the Study:

• To prospectively assess the early effects of sodium valproate on pro- and anticoagulatory factors.
• To evaluate changes in homocysteine and lipoprotein (a) levels in newly diagnosed epileptic children treated with valproate.
• To investigate the impact of short-term valproate therapy on specific coagulation factors.

Main Methods:

• Prospective systematic study involving 24 newly diagnosed epileptic children.
• Treatment with sodium valproate.
• Assessment of pro- and anticoagulatory factors, homocysteine, and lipoprotein (a).

Main Results:

• Sodium valproate significantly decreased factor VII levels.
• Other observed decreases included platelet count, factor VIII, Protein C, and fibrinogen.
• An increase in lipoprotein (a) levels was noted.

Conclusions:

• Valproate significantly reduces factor VII levels, even during short-term therapy in children.
• This study provides novel insights into the early hemostatic effects of valproate.
• Further research is warranted to understand the clinical implications of these hematological changes.